Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms.

The induction of apoptosis by the synthetic retinoid N-(4-hydroxyphenyl)retinamide (4HPR) has been documented in vitro in various cancer types. A role for reactive oxygen species (ROS) in apoptosis induced by 4HPR in some cancer cells has been demonstrated recently. We studied five different human head and neck and five lung cancer cell lines to determine whether the ROS play a general role in 4HPR-induced apoptosis. We found that 4HPR induced apoptosis in all of the cell lines; however, this effect was blocked by antioxidants in only 2 of the 10 cell lines. 4HPR induced a greater than 4-fold increase in the generation of intracellular ROS in these two cell lines compared with a much lower effect in other cell lines. Furthermore, these two cell lines were most sensitive to the induction of apoptosis by 4HPR. The level of the cellular antioxidant thiol and superoxide dismutase activity were relatively lower in cells, which responded to 4HPR with a high level of ROS generation. These results indicate that although ROS can mediate 4HPR-induced apoptosis in some cells, which may have a low endogenous cellular antioxidant levels, other mechanisms exist for 4HPR-induced apoptosis. One such mechanism may involve retinoic acid receptors (RARs) because an RAR antagonist was able to block partially 4HPR-induced apoptosis. In conclusion, 4HPR-induced apoptosis involves at least three different mechanisms, which are complex and can overlap in the same cell line: (a) one mechanism involving 4HPR-induced ROS; (b) one involving RARs; and (c) at least one that does not involve ROS or RARs and remains unclear.

[1]  R. Lotan,et al.  Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. , 1997, Cancer research.

[2]  R. Lotan,et al.  Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. , 1997, Journal of the National Cancer Institute.

[3]  E. Dmitrovsky N-(4-hydroxyphenyl)retinamide activation of a distinct pathway signaling apoptosis. , 1997, Journal of the National Cancer Institute.

[4]  John Calvin Reed,et al.  Role of antioxidants and intracellular free radicals in retinamide-induced cell death. , 1997, Carcinogenesis.

[5]  D. Fuchs,et al.  Reactive Oxygen and Apoptosis , 1997 .

[6]  G. Powis,et al.  Redox signaling and the control of cell growth and death. , 1997, Advances in pharmacology.

[7]  Y. Hiraku,et al.  Oxidative DNA damage and apoptosis induced by benzene metabolites. , 1996, Cancer research.

[8]  M. Takada,et al.  Involvement of hydrogen peroxide production in erbstatin-induced apoptosis in human small cell lung carcinoma cells. , 1996, Cancer research.

[9]  A. Fanjul,et al.  4-Hydroxyphenyl Retinamide Is a Highly Selective Activator of Retinoid Receptors* , 1996, The Journal of Biological Chemistry.

[10]  P. Chambon A decade of molecular biology of retinoic acid receptors , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  R. Lotan,et al.  Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  S. Fujieda,et al.  Involvement of intracellular glutathione in induction of apoptosis by cisplatin in a human pharyngeal carcinoma cell line. , 1996, Anticancer research.

[13]  C. Lau,et al.  Comparison of N-(4-hydroxyphenyl)retinamide and all-trans-retinoic acid in the regulation of retinoid receptor-mediated gene expression in human breast cancer cell lines. , 1996, Cancer research.

[14]  F. Zunino,et al.  Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression , 1996, International journal of cancer.

[15]  S. Orrenius,et al.  Signalling mechanisms and oxidative stress in apoptosis. , 1995, Toxicology letters.

[16]  S. Ramalingam,et al.  Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines. , 1995, Journal of the National Cancer Institute.

[17]  J. Lotem,et al.  Thymic abnormalities and enhanced apoptosis of thymocytes and bone marrow cells in transgenic mice overexpressing Cu/Zn‐superoxide dismutase: implications for Down syndrome. , 1995, The EMBO journal.

[18]  Z. Shao,et al.  N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. , 1995, Carcinogenesis.

[19]  W. Hong,et al.  Induction of apoptosis by retinoids in human cervical-carcinoma cell-lines. , 1995, International journal of oncology.

[20]  S. Orrenius,et al.  The role of intracellular oxidants in apoptosis. , 1995, Biochimica et biophysica acta.

[21]  C. Boni,et al.  Can fenretinide protect women against ovarian cancer? , 1995, Journal of the National Cancer Institute.

[22]  G. Powis,et al.  Redox signalling and the control of cell growth and death. , 1995, Pharmacology & therapeutics.

[23]  John Calvin Reed,et al.  Regulation of apoptosis induced by the retinoid N-(4-hydroxyphenyl) retinamide and effect of deregulated bcl-2. , 1995, Blood.

[24]  H. Namiki,et al.  Apoptotic cell death induced by serum and its prevention by thiols , 1994, Journal of cellular physiology.

[25]  U. Veronesi,et al.  N-(4-hydroxyphenyl)retinamide: a potent inducer of apoptosis in human neuroblastoma cells. , 1994, Journal of the National Cancer Institute.

[26]  U. Veronesi,et al.  Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide. , 1994, Cancer research.

[27]  S. Ménard,et al.  N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. , 1993, Cancer research.

[28]  D. Bredesen,et al.  Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. , 1993, Science.

[29]  F. Formelli,et al.  Synthetic retinoid fenretinide is effective against a human ovarian carcinoma xenograft and potentiates cisplatin activity. , 1993, Cancer research.

[30]  Z. Oltvai,et al.  Bcl-2 functions in an antioxidant pathway to prevent apoptosis , 1993, Cell.

[31]  M. Clerici,et al.  Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  K. Pienta,et al.  Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide. , 1993, Cancer research.

[33]  M. Sporn,et al.  Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. , 1991, Cancer research.

[34]  R. Mehta,et al.  Suppression of rat mammary cancer development by N-(4-hydroxyphenyl)retinamide (4-HPR) following surgical removal of first palpable tumor. , 1989, Carcinogenesis.

[35]  W Malone,et al.  Tolerability of the synthetic retinoid Fenretinide (HPR). , 1989, European journal of cancer & clinical oncology.